Dermatomycoses Market Report 2026

The dermatomycoses market size has grown strongly in recent years. It will grow from $14.81 billion in 2025 to $15.59 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to humid climate exposure, poor hygiene conditions, reliance on topical drugs, limited awareness, hospital-based treatment.

The dermatomycoses market size is expected to see strong growth in the next few years. It will grow to $19.11 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to improved antifungal formulations, increasing skin infection incidence, growing outpatient care, rising hygiene awareness, expansion of dermatology services. Major trends in the forecast period include rising prevalence of fungal skin infections, increased use of topical antifungals, growth of combination antifungal therapies, expansion of outpatient dermatology care, focus on recurrence prevention.

The rising prevalence of fungal infections is expected to drive the growth of the dermatomycoses market in the coming years. Fungal infections are conditions caused by fungi that affect the skin, nails, hair, or internal organs, leading to a range of health complications. The overuse of broad-spectrum antibiotics disrupts the body’s natural microbiome, creating favorable conditions for fungal growth and infection. This imbalance weakens the body’s innate defense systems, increasing susceptibility to opportunistic fungal infections. Dermatomycoses, caused by dermatophytes, yeasts, and molds, account for fungal diseases that affect multiple tissues and result in common superficial and systemic infections. For instance, in November 2023, according to the UK Health Security Agency, a UK-based public health organization responsible for safeguarding public health from infectious diseases, global estimates show an annual incidence of 6.5 million invasive fungal infections, leading to around 3.8 million deaths, with 2.5 million directly attributed to these infections. Therefore, the increasing prevalence of fungal infections is contributing to the growth of the dermatomycoses market.

The expansion of the aging population is also expected to propel the growth of the dermatomycoses market going forward. An aging population refers to the growing number and share of individuals aged 65 years and above within a country’s demographic profile. This increase is largely driven by the baby boomer generation reaching retirement age, resulting in a higher proportion of elderly individuals in the population. The expanding elderly population supports a higher incidence of fungal skin infections, as older adults often experience weakened immune responses, reduced skin barrier function, and age-related physiological changes that increase susceptibility to dermatomycoses such as athlete’s foot, ringworm, and nail infections. For instance, in July 2024, according to the UK Parliament’s House of Commons Library, a UK-based government body, there were 12.7 million people aged 65 or older in the UK in 2022, accounting for 19% of the total population. This figure is projected to rise to 22.1 million by 2072, representing 27% of the population. Therefore, the growth in the aging population is driving the expansion of the dermatomycoses market.

Major companies operating in the dermatomycoses market are concentrating on developing investigational new drug candidates to enhance onychomycosis treatment outcomes and improve therapeutic effectiveness. An investigational new drug (IND) candidate refers to a pharmaceutical compound that is in preclinical or clinical development stages to assess its safety, efficacy, and regulatory potential prior to approval for clinical use. For instance, in January 2024, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA), a US-based regulatory authority, for its investigational new drug candidate VTR-297 for the treatment of onychomycosis. VTR-297 is differentiated as a topical antifungal candidate due to its histone deacetylase (HDAC) inhibitor properties, setting it apart from conventional antifungal therapies. This mechanism targets the underlying drivers of fungal growth and demonstrates strong antifungal activity against dermatophytes and other fungi. Such an innovative approach has the potential to provide faster and more effective treatment outcomes while reducing the risk of recurrence, addressing a key unmet need in onychomycosis management.

Major companies operating in the dermatomycoses market are Pfizer Inc., Bayer AG, Saphnix Life Sciences, MITS Healthcare Private Limited, Weefsel Pharma, AdvaCare Pharma, Associated Biotech, Healthy Life Pharma Private Limited, Blueberry Therapeutics Ltd., Livealth Biopharma Pvt. Ltd., LGM Pharma, SiNi Pharma Pvt. Ltd., Joshi Agrochem Pharma Private Limited, Wellona Pharma, Abiba Pharmacia Pvt. Ltd., Vee Excel Drugs & Pharmaceuticals Pvt. Ltd., Femcorp Pharma, Lexicare Pharma Pvt. Ltd., Glamris Dermacare, Henin Lukinz.

North America was the largest region in the dermatomycoses market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatomycoses market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dermatomycoses market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the dermatomycoses market by increasing costs of imported antifungal drugs and pharmaceutical ingredients. Hospitals and clinics in North America and Europe are most affected due to reliance on imported medications, while Asia-Pacific faces higher formulation costs. These tariffs are increasing treatment expenses by raising procurement costs for topical and systemic antifungal therapies, contributing to higher pricing for patients and healthcare providers and potentially limiting access to timely treatment in cost-sensitive settings. However, they are encouraging domestic antifungal production, greater localization of active pharmaceutical ingredient manufacturing, and increased investment in regional pharmaceutical capabilities to reduce import dependence and improve supply resilience over the long term.

The dermatomycoses market research report is one of a series of new reports that provides dermatomycoses market statistics, including dermatomycoses industry global market size, regional shares, competitors with a dermatomycoses market share, detailed dermatomycoses market segments, market trends and opportunities, and any further data you may need to thrive in the dermatomycoses industry. This dermatomycoses market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dermatomycoses are a category of fungal infections that affect the skin, hair, and nails and are mainly caused by dermatophytes, yeasts, or molds. These infections commonly result in itching, scaling, redness, and inflammation of the skin, negatively affecting overall skin health. Treatment primarily focuses on eradicating the fungal infection, relieving symptoms, and preventing recurrence through antifungal therapies, proper hygiene, and effective skin care practices.

The key drug types used for dermatomycoses include corticosteroids, corticosteroid-sparing agents, immunosuppressives, immunomodulators, antifungals, and others. Corticosteroids are anti-inflammatory medications that help minimize swelling, redness, and itching associated with skin conditions. These drugs are administered through various routes such as oral, parenteral, topical, and others, and are utilized by end users including hospitals, specialty clinics, and others.

The dermatomycoses market consists of sales of barrier creams or protective skin creams, medicated soaps and body washes, and cryotherapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.